|
1
|
Hegi ME, Diserens AC, Gorlia T, Hamou MF,
de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani
L, et al: MGMT gene silencing and benefit from temozolomide in
glioblastoma. N Engl J Med. 352:997–1003. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Weller M, Tabatabai G, Kästner B, Felsberg
J, Steinbach JP, Wick A, Schnell O, Hau P, Herrlinger U, Sabel MC,
et al: MGMT Promoter methylation is a strong prognostic biomarker
for benefit from dose-intensified temozolomide rechallenge in
progressive glioblastoma: The DIRECTOR trial. Clin Cancer Res.
21:2057–2064. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Aum DJ, Kim DH, Beaumont TL, Leuthardt EC,
Dunn GP and Kim AH: Molecular and cellular heterogeneity: The
hallmark of glioblastoma. Neurosurg Focus. 37:E112014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bonavia R, Inda MM, Cavenee WK and Furnari
FB: Heterogeneity maintenance in glioblastoma: A social network.
Cancer Res. 71:4055–4060. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Raja R, Sinha N, Saini J, Mahadevan A, Rao
KN and Swaminathan A: Assessment of tissue heterogeneity using
diffusion tensor and diffusion kurtosis imaging for grading
gliomas. Neuroradiology. 58:1217–1231. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Parker NR, Hudson AL, Khong P, Parkinson
JF, Dwight T, Ikin RJ, Zhu Y, Cheng ZJ, Vafaee F, Chen J, et al:
Intratumoral heterogeneity identified at the epigenetic, genetic
and transcriptional level in glioblastoma. Sci Rep. 6:224772016.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Brandes AA, Franceschi E, Tosoni A,
Bartolini S, Bacci A, Agati R, Ghimenton C, Turazzi S, Talacchi A,
Skrap M, et al: O(6)-methylguanine DNA-methyltransferase
methylation status can change between first surgery for newly
diagnosed glioblastoma and second surgery for recurrence: Clinical
implications. Neuro Oncol. 12:283–288. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Parkinson JF, Wheeler HR, Clarkson A,
McKenzie CA, Biggs MT, Little NS, Cook RJ, Messina M, Robinson BG
and McDonald KL: Variation of O(6)-methylguanine-DNA
methyltransferase (MGMT) promoter methylation in serial samples in
glioblastoma. J Neurooncol. 87:71–78. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Park CK, Kim JE, Kim JY, Song SW, Kim JW,
Choi SH, Kim TM, Lee SH, Kim IH and Park SH: The changes in MGMT
promoter methylation status in initial and recurrent glioblastomas.
Transl Oncol. 5:393–397. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Andronesi OC, Kim GS, Gerstner E,
Batchelor T, Tzika AA, Fantin VR, Vander Heiden MG and Sorensen AG:
Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by
in vivo spectral-editing and 2D correlation magnetic resonance
spectroscopy. Sci Transl Med. 4:116ra42012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Choi C, Ganji SK, DeBerardinis RJ,
Hatanpaa KJ, Rakheja D, Kovacs Z, Yang XL, Mashimo T, Raisanen JM,
Marin-Valencia I, et al: 2-hydroxyglutarate detection by magnetic
resonance spectroscopy in IDH-mutated patients with gliomas. Nat
Med. 18:624–629. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Okita Y, Nonaka M, Shofuda T, Kanematsu D,
Yoshioka E, Kodama Y, Mano M, Nakajima S and Kanemura Y:
(11)C-methinine uptake correlates with MGMT promoter methylation in
nonenhancing gliomas. Clin Neurol Neurosurg. 125:212–216. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Pope WB, Prins RM, Albert Thomas M,
Nagarajan R, Yen KE, Bittinger MA, Salamon N, Chou AP, Yong WH,
Soto H, et al: Non-invasive detection of 2-hydroxyglutarate and
other metabolites in IDH1 mutant glioma patients using magnetic
resonance spectroscopy. J Neurooncol. 107:197–205. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Saito T, Maruyama T, Muragaki Y, Tanaka M,
Nitta M, Shinoda J, Aki T, Iseki H, Kurisu K and Okada Y:
11C-methionine uptake correlates with combined 1p and 19q loss of
heterozygosity in oligodendroglial tumors. AJNR Am J Neuroradiol.
34:85–91. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shinozaki N, Uchino Y, Yoshikawa K,
Matsutani T, Hasegawa A, Saeki N and Iwadate Y: Discrimination
between low-grade oligodendrogliomas and diffuse astrocytoma with
the aid of 11C-methionine positron emission tomography. J
Neurosurg. 114:1640–1647. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Okita Y, Kinoshita M, Goto T, Kagawa N,
Kishima H, Shimosegawa E, Hatazawa J, Hashimoto N and Yoshimine T:
(11)C-methionine uptake correlates with tumor cell density rather
than with microvessel density in glioma: A stereotactic
image-histology comparison. Neuroimage. 49:2977–2982. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Esteller M, Hamilton SR, Burger PC, Baylin
SB and Herman JG: Inactivation of the DNA repair gene
O6-methylguanine-DNA methyltransferase by promoter hypermethylation
is a common event in primary human neoplasia. Cancer Res.
59:793–797. 1999.PubMed/NCBI
|
|
18
|
Berger G, Maziere M, Knipper R, Prenant C
and Comar D: Automated synthesis of 11C-labelled
radiopharmaceuticals: Imipramine, chlorpromazine, nicotine and
methionine. Int J Appl Radiat Isot. 30:393–399. 1979. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Knudsen GM, Pettigrew KD, Patlak CS, Hertz
MM and Paulson OB: Asymmetrical transport of amino acids across the
blood-brain barrier in humans. J Cereb Blood Flow Metab.
10:698–706. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Souba WW and Pacitti AJ: How amino acids
get into cells: Mechanisms, models, menus, and mediators. JPEN J
Parenter Enteral Nutr. 16:569–578. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Christmann M, Nagel G, Horn S, Krahn U,
Wiewrodt D, Sommer C and Kaina B: MGMT activity, promoter
methylation and immunohistochemistry of pretreatment and recurrent
malignant gliomas: A comparative study on astrocytoma and
glioblastoma. Int J Cancer. 127:2106–2118. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bergström M, Lundqvist H, Ericson K, Lilja
A, Johnström P, Långström B, von Holst H, Eriksson L and Blomqvist
G: Comparison of the accumulation kinetics of
L-(methyl-11C)-methionine and D-(methyl-11C)-methionine in brain
tumors studied with positron emission tomography. Acta Radiol.
28:225–229. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kato T, Shinoda J, Nakayama N, Miwa K,
Okumura A, Yano H, Yoshimura S, Maruyama T, Muragaki Y and Iwama T:
Metabolic assessment of gliomas using 11C-methionine, [18F]
fluorodeoxyglucose and 11C-choline positron-emission tomography.
AJNR Am J Neuroradiol. 29:1176–1182. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ishiwata K, Ido T, Abe Y, Matsuzawa T and
Iwata R: Tumor uptake studies of
S-adenosyl-L-[methyl-11C]methionine and L-[methyl-11C]methionine.
Int J Rad Appl Instrum B. 15:123–126. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Baldessarini RJ and Kopin IJ:
S-adenosylmethionine in brain and other tissues. J Neurochem.
13:769–777. 1966. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Andreoli VM, Agnoli A and Fazio C:
Transmethylations and the central nervous system. Springer-Verlag;
Berlin; 1978, View Article : Google Scholar
|
|
27
|
Ishiwata K, Vaalburg W, Elsinga PH, Paans
AM and Woldring MG: Comparison of L-[1-11C]methionine and
L-methyl-[11C]methionine for measuring in vivo protein synthesis
rates with PET. J Nucl Med. 29:1419–1427. 1988.PubMed/NCBI
|
|
28
|
Wiewrodt D, Nagel G, Dreimüller N,
Hundsberger T, Perneczky A and Kaina B: MGMT in primary and
recurrent human glioblastomas after radiation and chemotherapy and
comparison with p53 status and clinical outcome. Int J Cancer.
122:1391–1399. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Choi H, Bang JI, Cheon GJ, Kim YH, Park
CK, Park SH, Kang KW, Chung JK, Kim EE and Lee DS:
18F-fluorodeoxyglucose and11C-methionine
positron emission tomography in relation to methyl-guanine
methyltransferase promoter methylation in high-grade gliomas. Nucl
Med Commun. 36:211–218. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lopci E, Riva M, Olivari L, Raneri F,
Soffietti R, Piccardo A, Bizzi A, Navarria P, Ascolese AM, Rudà R,
et al: Prognostic value of molecular and imaging biomarkers in
patients with supratentorial glioma. Eur J Nucl Med Mol Imaging.
44:1155–1164. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Roelcke U, Radü EW, von Ammon K, Hausmann
O, Maguire RP and Leenders KL: Alteration of blood-brain barrier in
human brain tumors: Comparison of [18F]fluorodeoxyglucose,
[11C]methionine and rubidium-82 using PET. J Neurol Sci. 132:20–27.
1995. View Article : Google Scholar : PubMed/NCBI
|
